Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract: The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X? is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl} 5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded,

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X? is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is exclude

Abstract: The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X? is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded,

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: A projector includes a dimming device that moves a light-shielding member for shielding light to adjust the amount of light emitted from a light source, a housing that accommodates the dimming device, a temperature detection section that detects an internal temperature of the housing, and a control section that controls an adjustment state of the amount of light through the dimming device. The control section starts a control of the dimming device when the temperature detected by the temperature detection section is set to equal to or higher than a predetermined temperature.

Abstract: A projector includes a dimming device that moves a light-shielding member for shielding light to adjust the amount of light emitted from a light source, a housing that accommodates the dimming device, a temperature detection section that detects an internal temperature of the housing, and a control section that controls an adjustment state of the amount of light through the dimming device. The control section starts a control of the dimming device when the temperature detected by the temperature detection section is set to equal to or higher than a predetermined temperature.

Abstract: A projector includes: a projecting unit that projects a first image on a projection target area; an imaging unit that picks up a first pickup image of the projection target area during the projection of the first image and picks up a second pickup image of the projection target area during single-color image projection or during non-projection with automatic exposure; an imaging control unit that changes an exposure setting value on the basis of the first pickup image and an exposure setting value during the last imaging and causes the imaging unit to pick up an image of the projection target area during the projection of the first image at the exposure setting value after the change and regenerate the first pickup image; a first coordinate information generating unit that generates first coordinate information; and a second coordinate information generating unit that generates second coordinate information.

Abstract: A projector includes: a storing unit that stores setting data indicating a manual trapezoidal distortion correction system selected out of plural kinds of manual trapezoidal distortion correction systems; an operation unit that generates operation information; an imaging unit that picks up an image of a projection target area and generates a pickup image; an automatic trapezoidal distortion correction unit that performs automatic trapezoidal distortion correction; a projecting unit that projects, after the automatic trapezoidal distortion correction is performed, irrespectively of the manual trapezoidal distortion correction system indicated by the setting data, an adjustment instruction image for urging adjustment of a vertex position of a display planned area of the image in the projection target area; and a manual trapezoidal distortion correction unit that performs manual trapezoidal distortion correction on the basis of operation information indicating an adjustment instruction for the vertex position.

Abstract: The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.

Abstract: A projector includes: a projecting unit that projects a first image on a projection target area; an imaging unit that picks up a first pickup image of the projection target area during the projection of the first image and picks up a second pickup image of the projection target area during single-color image projection or during non-projection with automatic exposure; an imaging control unit that changes an exposure setting value on the basis of the first pickup image and an exposure setting value during the last imaging and causes the imaging unit to pick up an image of the projection target area during the projection of the first image at the exposure setting value after the change and regenerate the first pickup image; a first coordinate information generating unit that generates first coordinate information; and a second coordinate information generating unit that generates second coordinate information.

Abstract: A projector includes: a storing unit that stores setting data indicating a manual trapezoidal distortion correction system selected out of plural kinds of manual trapezoidal distortion correction systems; an operation unit that generates operation information; an imaging unit that picks up an image of a projection target area and generates a pickup image; an automatic trapezoidal distortion correction unit that performs automatic trapezoidal distortion correction; a projecting unit that projects, after the automatic trapezoidal distortion correction is performed, irrespectively of the manual trapezoidal distortion correction system indicated by the setting data, an adjustment instruction image for urging adjustment of a vertex position of a display planned area of the image in the projection target area; and a manual trapezoidal distortion correction unit that performs manual trapezoidal distortion correction on the basis of operation information indicating an adjustment instruction for the vertex position.

Abstract: The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.

Abstract: A transmitting section spontaneously transmits a command including device information relating to a field device, to a field server. An updating section receives commands including device information which is spontaneously transmitted from field devices, and updates a database on the basis of the device information. Based on the device information stored in the database, a server communicating section communicates with the field devices.

Abstract: The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X? is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is exclude